Based on the Eupraxia Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Eupraxia Pharmaceuticals Inc is not available over the next 12 months. Eupraxia Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Eupraxia Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Eupraxia Pharmaceuticals Inc’s stock price was CAD 4.34. Eupraxia Pharmaceuticals Inc’s stock price has changed by +2.36% over the past week, -10.52% over the past month and -18.11% over the last year.
No recent analyst target price found for Eupraxia Pharmaceuticals Inc
No recent average analyst rating found for Eupraxia Pharmaceuticals Inc
Company Overview Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. Read Less
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment o...Read More
Frequently Asked Questions About Eupraxia Pharmaceuticals Inc (EPRX:CA) Stock
Stock Target Advisor's fundamental analysis for Eupraxia Pharmaceuticals Inc's stock is Bearish.
Unfortunately we do not have enough data on EPRX:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on EPRX:CA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on EPRX:CA's stock to indicate if its overvalued.
The last closing price of EPRX:CA's stock was CAD 4.34.
The most recent market capitalization for EPRX:CA is CAD 0.16B.
Unfortunately we do not have enough analyst data on EPRX:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Eupraxia Pharmaceuticals Inc's stock.
As per our most recent records Eupraxia Pharmaceuticals Inc has 29 Employees.
Eupraxia Pharmaceuticals Inc's registered address is 2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4.
You can get more information about it from Eupraxia Pharmaceuticals Inc's website at https://www.eupraxiapharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Eupraxia Pharmaceuticals Inc (EPRX:CA) Stock
Stock Target Advisor's fundamental analysis for Eupraxia Pharmaceuticals Inc's stock is Bearish.
Unfortunately we do not have enough data on EPRX:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on EPRX:CA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on EPRX:CA's stock to indicate if its overvalued.
The last closing price of EPRX:CA's stock was CAD 4.34.
The most recent market capitalization for EPRX:CA is CAD 0.16B.
Unfortunately we do not have enough analyst data on EPRX:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Eupraxia Pharmaceuticals Inc's stock.
As per our most recent records Eupraxia Pharmaceuticals Inc has 29 Employees.
Eupraxia Pharmaceuticals Inc's registered address is 2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4.
You can get more information about it from Eupraxia Pharmaceuticals Inc's website at https://www.eupraxiapharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for EPRX:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
